Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part VI--The recent rise and fall of the HDL-boosting drug torceptrapib.

Urologic nursing : official journal of the American Urological Association Allied

Volumn 27, Issue 2, 2007, Pages 169-173

  Moyad, Mark A ^a   Merrick, Gregory S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; QUINOLINE DERIVATIVE; TORCETRAPIB;

ARTICLE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG INDUSTRY; ECONOMICS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KINESIOTHERAPY; MENTAL STRESS; MORTALITY; PATIENT EDUCATION; PHASE 3 CLINICAL TRIAL; RISK REDUCTION; SMOKING CESSATION; UNITED STATES; URINARY TRACT DISEASE; WEIGHT REDUCTION;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS, PHASE III; DRUG INDUSTRY; EXERCISE THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; PATIENT EDUCATION; QUINOLINES; RISK REDUCTION BEHAVIOR; SMOKING CESSATION; STRESS, PSYCHOLOGICAL; UNITED STATES; UROLOGIC DISEASES; WEIGHT LOSS;

EID: 34250313594     PISSN: 1053816X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)